- Global Pharma News & Resources

Global Melanoma Disease Insights and Market Report 2020-2026: Sales and Patient Forecasts by Key Therapies - Opdivo, Keytruda, Tafinlar, LN-144, Bempegaldesleukin, Braftovi, & Yervoy -

DUBLIN--(BUSINESS WIRE)--The "Melanoma - Disease Insights and Market Forecasts to 2026" report has been added to's offering.

"Melanoma: Disease Insights and Market Forecasts to 2026" report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of Melanoma disease in the US, EU5 (Germany, France, Italy, Spain, UK), and Japan and the historical & forecasted market size, for Melanoma, drug wise in $ sales and patient numbers at global level and in the US, EU5 (Germany, France, Italy, Spain, UK), Australia and Canada till 2026.

Disease Indication Overview:

This section of the report gives the overview of Melanoma disease indication in detail. The section highlights the basic definition, causes and symptoms of disease and details the types of Melanoma disease. Further details on the profile of Melanoma patients, symptoms experienced by the patients, and disease progression in patients are outlined in the report. The report further highlights the multiple methods through which the patient can be diagnosed for Melanoma disease.

Epidemiology Forecasts to 2026:

This section of the report provides the overview of Melanoma diagnosed prevalent and treated patients in the US, EU5 and Japan market year wise starting from 2018 till 2026. The epidemiology numbers in the report have been derived based on numerous studies, survey reports and views of key opinion leaders.

Drugs Overview and Attribute Analysis:

This part of the report highlights the importance of factors influencing the physician prescription decisions in Melanoma disease including efficacy factors, tolerability factors, monitoring requirements and pricing factors.

The report further details the drugs prescribed or expected to be prescribed in Melanoma disease by physicians in terms of details about the formulation, molecule, mode of administration and mechanism of action of the drugs, their patent and trial details and the expected impact of drug in the Breast market.

The report further conducts a detailed drug attribute analysis of the drugs currently prescribed or expected to be prescribed in the disease on the parameters of Efficacy, Safety and Tolerability, Convenience of Monitoring and Dosing and Drug's coverage of the target patient pool.

Why Purchase the Report:

  • Robust Market and Drug forecast available at country level
  • Forecast in terms of both $ sales and Patient Numbers
  • Current and Forecasted Drug treated and Diagnosed Prevalent Patient pool
  • Detailed Drug Attribute analysis on multiple Clinical Parameters
  • Multiple Countries coverage
  • Current Marketed and Pipeline Drugs coverage
  • Detailed Disease Insights coverage

Key Topics Covered:

1 List of Tables & Figures

2 Executive Summary

2.1 Key Metrics

3. Disease Overview

3.1 Disease Definition

3.2 Disease Etiology and Pathophysiology

3.2.1 Etiology

3.2.2 Pathophysiology

3.2.3 Impact on Quality of Life

3.3 Symptoms of the Disease

3.4 Disease Diagnosis

3.5 Treatment Guidelines

3.6 Key unmet needs

4. Disease Epidemiology

4.1 Patient Number projections by Country

4.1.1 France

4.1.2 Germany

4.1.3 Italy

4.1.4 Spain

4.1.5 United Kingdom

4.1.6 United States

4.1.7 Japan

5 Physician's Insights

5.1 Factors impacting a physician's prescription decision:

5.1.1 Efficacy

5.1.2 Safety

5.1.3 Monitoring requirements

5.1.4 Pricing and Reimbursement

6 Competitive Assessment and Attribute Analysis - Key Therapies

6.1 Opdivo

6.1.1 Overview

6.1.2 Patent Information

6.1.3 Clinical Status and Trial Details

6.1.4 Attribute Analysis

6.1.5 Impact of Drug on the market

6.2 Keytruda

6.3 Tafinlar

6.4 LN-144

6.5 Bempegaldesleukin

6.6 Braftovi

6.7 Yervoy

7 Pipeline Assessment

7.1 Overview

7.2 Strategic Review of the Pipeline

7.3 Pipeline analysis by Phases of Development

7.3.1 NDA/BLA Filed

7.3.2 Phase III Pipeline

7.3.3 Phase II Pipeline

7.3.4 Phase I Pipeline

7.3.5 Preclinical Pipeline

7.3.6 Discovery Pipeline

7.4 Pipeline Analysis by Mechanism of Action

7.5 Pipeline Analysis by Novelty of Mechanism of Action

7.6 Suspended and Terminated products

8. Market Outlook

8.1 Major Markets Overview

8.1.1 Sales Forecast 2018-2026

8.1.2 Patient Forecast 2018-2026

8.2 Analysis by Country Sales and Patients forecast 2018-2026

8.2.1 France

8.2.2 Germany

8.2.3 Italy

8.2.4 Spain

8.2.5 United Kingdom

8.2.6 United States

8.2.7 Japan

8.3 Key events

8.4 Key Growth Drivers and Barriers

9 Sales and Patient Forecast for Key Drugs Forecasts till 2026

9.1 Opdivo

9.1.1 Value sales in USD for Melanoma Disease

9.1.2 Value sales by key Geographies in USD

9.1.3 Absolute Patient Numbers in Melanoma Disease

9.1.4 Patient Numbers by key Geographies

9.2 Keytruda

9.3 Tafinlar

9.4 LN-144

9.5 Bempegaldesleukin

9.6 Braftovi

9.7 Yervoy

10. Appendix

Companies Mentioned

  • Bristol-Myers Squibb
  • Novartis
  • Ono Pharmaceutical
  • Iovance Biotherapeutics
  • Otsuka Holdings
  • Merck & Co
  • Array BioPharma
  • Pfizer
  • Nektar Therapeutics

For more information about this report visit

Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Editor Details

  • Company:
    • Businesswire
Last Updated: 06-May-2021